TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33885704

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) starting dose of 50 Gy in 5 fractions (central lung, mediastinal/cervical lymph node), 45 Gy in 3 fractions (peripheral lung, abdominal-pelvic, liver), and 30 Gy in 3 fractions (bone/osseous, spinal/paraspinal)
Number of subjects: 35
Study: 32072763

Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 2.5 mg once daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 10 mg once daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 25 mg once daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 50 mg once daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 35044431

Group type: EXPERIMENTAL
Intervention: Synthetic mesh
Number of subjects: 253

Group type: COMPARATOR
Intervention: Biologic mesh
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Both meshes
Number of subjects: 253
Study: 33085532

Group type: EXPERIMENTAL
Intervention: Own mother's milk odor
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Another mother's milk odor
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no milk odor)
Number of subjects: 90
Study: 33237242

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 24% EDTA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: RelyX U200 (RX)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Multilink Speed (ML)
Number of subjects: 78
Study: 35695053

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulin (IVIG) at a dose of 5 g/day for 3 days (total 15 g or 0.3 g/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulin (IVIG)
Number of subjects: 80
Study: 34474583

Group type: EXPERIMENTAL
Intervention: Rivaroxaban or rivaroxaban plus an antiplatelet agent
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 2215
Study: 35866981

Group type: EXPERIMENTAL
Intervention: 7% sodium citrate with methylene blue and parabens
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 400
Study: 34961782

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Etodolac (ETO)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Ketorolac (KET)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Ibuprofen (IBU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Loxoprofen (LOX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol 750 mg (rescue analgesics)
Number of subjects: 100
Study: 35590400

Group type: EXPERIMENTAL
Intervention: Gain Frame Messages (GFM)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Loss Frame Messages (LFM)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 270
Study: 33203880

Group type: EXPERIMENTAL
Intervention: 3YF-lipin-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: p-Tyr-lipin-1 levels
Number of subjects: 0
Study: 34287970

Group type: EXPERIMENTAL
Intervention: 5 mg apraglutide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg apraglutide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 34955789

Group type: EXPERIMENTAL
Intervention: Active tDCS with mindfulness practice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS with mindfulness practice
Number of subjects: 30
Study: 34933309

Group type: EXPERIMENTAL
Intervention: Warm water with Sinapis nigra (MU)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Warm water with Zingiber officinale (GI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Warm water only (WA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Warm water with GI
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Warm water with MU
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: General well-being and sleep quality assessments
Number of subjects: 17
Study: 32072772

Group type: EXPERIMENTAL
Intervention: Exam room educational poster (English and Spanish)
Number of subjects: 965
Study: 35938500

Group type: EXPERIMENTAL
Intervention: Parent-focused social marketing campaign promoting healthy children's meals
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1686
Study: 34414672

Group type: COMPARATOR
Intervention: Enpatoran 1, 3, 9, 25, 50, 100, or 200 mg single dose
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enpatoran 9, 25, or 200 mg once daily for 14 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enpatoran 25 or 50 mg twice daily for 14 days
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Enpatoran 25 mg single dose with food
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Enpatoran 200 mg single dose
Number of subjects: 96
Study: 32942788

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate (TA) 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate (TA) 20 mg
Number of subjects: 30
Study: 35027938

Group type: EXPERIMENTAL
Intervention: Inner Engineering Online (IEO) program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (active control)
Number of subjects: 71
Study: 32329766

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular naloxone
Number of subjects: 0
Study: 34321056

Group type: EXPERIMENTAL
Intervention: Tuina with herbal ointment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Herbal ointment (control group)
Number of subjects: 84
Study: 33038022

Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention (4-week program with four sessions: two face-to-face and two telephone follow-ups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (renal education and social chats)
Number of subjects: 0
Study: 34979880

Group type: EXPERIMENTAL
Intervention: Sub-threshold vibration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supra-threshold vibration
Number of subjects: 19

Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 19
Study: 33730928

Group type: EXPERIMENTAL
Intervention: 0.1 μg/kg
Number of subjects: 136

Group type: COMPARATOR
Intervention: 0.3 μg/kg
Number of subjects: 136

Group type: COMPARATOR
Intervention: 0.5 μg/kg
Number of subjects: 136

Group type: COMPARATOR
Intervention: 1.0 μg/kg
Number of subjects: 136
Study: 35742483

Group type: EXPERIMENTAL
Intervention: Personalized VREs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard VREs
Number of subjects: 20
Study: 32503545

Group type: EXPERIMENTAL
Intervention: 2-week medical respite care stay at a Red Cross facility
Number of subjects: 96

Group type: COMPARATOR
Intervention: usual care (discharged without extra help)
Number of subjects: 96
Study: 35380356

Group type: EXPERIMENTAL
Intervention: 18 g/day of MCT oil
Number of subjects: 63

Group type: COMPARATOR
Intervention: Matching placebo formula (control)
Number of subjects: 63
Study: 34080044

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 34599865

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (SC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium acetate (CA)
Number of subjects: 50
Study: 35032434

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 495

Group type: COMPARATOR
Intervention: Pomalidomide plus dexamethasone
Number of subjects: 495
Study: 33357055

Group type: EXPERIMENTAL
Intervention: Intervention: Not specified in the abstract.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control: Not specified in the abstract.
Number of subjects: 0
Study: 34388037

Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training (MCPC) delivered across four 45- to 60-minute videoconference sessions.
Number of subjects: 30
Study: 33686119

Group type: EXPERIMENTAL
Intervention: Intervention Success Group (PDA closure achieved)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intervention Failure Group (PDA closure not achieved)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo Group
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low Risk Group
Number of subjects: 73
Study: 34445834

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (400 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (control group, average calcium intake 400 mg/d)
Number of subjects: 64
Study: 32070034

Group type: EXPERIMENTAL
Intervention: Height‐adjustable workstation with supporting behaviour change strategies
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 146
Study: 35460145

Group type: EXPERIMENTAL
Intervention: Jujube syrup, consumed twice a day for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, consumed twice a day for 8 weeks
Number of subjects: 46
Study: 34126605

Group type: EXPERIMENTAL
Intervention: DIBH
Number of subjects: 80

Group type: COMPARATOR
Intervention: FB
Number of subjects: 80
Study: 34332638

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32402060

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9)
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Obesity Grade 1 (BMI 30-34.9)
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Low body weight (BMI < 22)
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Continued 2-year weight loss
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 12521
Study: 34521417

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 233

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 233
Study: 36007709

Group type: EXPERIMENTAL
Intervention: SAATH intervention (group exercise classes, mother-daughter discussions, peer group discussions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (PA education materials)
Number of subjects: 160
Study: 33183463

Group type: EXPERIMENTAL
Intervention: Nanoparticle-loaded edaravone treatment (NET)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined treatment (CT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Edaravone treatment (ET)
Number of subjects: 120
Study: 35367918

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Health education (HealthEd)
Number of subjects: 119
Study: 33094682

Group type: EXPERIMENTAL
Intervention: meloxicam IV 30 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 32513473

Group type: EXPERIMENTAL
Intervention: CES-D scale scoring with a cut-off score of 30
Number of subjects: 348
Study: 32726514

Group type: EXPERIMENTAL
Intervention: Subcutaneous sarilumab (150 or 200 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intravenous tocilizumab (4 or 8 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both drugs (sarilumab and tocilizumab)
Number of subjects: 101
Study: 32767208

Group type: EXPERIMENTAL
Intervention: Gaming group (first-person shooter game)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 34158245

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg PO daily with paclitaxel 80 mg/m2 IV weekly ×12 followed by doxorubicin 24 mg/m2 IV weekly + cyclophosphamide 60 mg/m2 PO daily with G-CSF support
Number of subjects: 70
Study: 32971253

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 40226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40226
Study: 36355739

Group type: EXPERIMENTAL
Intervention: Pattern recognition control
Number of subjects: 2

Group type: COMPARATOR
Intervention: Direct control
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: EMG signal analysis
Number of subjects: 2
Study: 34096845

Group type: EXPERIMENTAL
Intervention: Health care-specific websites (eg, Healthgrades, Zocdoc, Vitals, WebMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General consumer sites (eg, Google, Yelp)
Number of subjects: 0
Study: 32204706

Group type: EXPERIMENTAL
Intervention: Children with ASD (case group)
Number of subjects: 30
Study: 34452959

Group type: EXPERIMENTAL
Intervention: High fibre supplement (resistant starch)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (digestible starch)
Number of subjects: 60
Study: 34817559

Group type: EXPERIMENTAL
Intervention: PSA screening (three invitations at 4-year intervals from 1996 to 2007)
Number of subjects: 78606

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 78606
Study: 33619944

Group type: EXPERIMENTAL
Intervention: Home-based cardiac telerehabilitation (HBCT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Center-based cardiac rehabilitation (CBCR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups (HBCT and CBCR)
Number of subjects: 44
Study: 32796391

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory combination therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 34644372

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 296

Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV)
Number of subjects: 296
Study: 34706841

Group type: EXPERIMENTAL
Intervention: MINHAI PCV13
Number of subjects: 900

Group type: COMPARATOR
Intervention: Hib
Number of subjects: 900
Study: 32216832

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) combined with bright light therapy (BLT) - one face-to-face session on sleep strategies, one telephone call, seven email packages, and wearing Luminette® light glasses for 20 minutes each morning for 6 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation audio-enhanced treatment as usual (TAU+) - two relaxation audio tracks via email.
Number of subjects: 0
Study: 32203960

Group type: EXPERIMENTAL
Intervention: Static half squat plus WBV (HSV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Static half squat without WBV (HSWV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest (REST)
Number of subjects: 12
Study: 34606090

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygenation targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Number of subjects: 0
Study: 32845062

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 363

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 363
Study: 34297441

Group type: EXPERIMENTAL
Intervention: Shape Up-LD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study: 34916532

Group type: EXPERIMENTAL
Intervention: star‐VIBE sequence (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3D‐VIBE sequence (Group B)
Number of subjects: 60
Study: 36060925

Group type: EXPERIMENTAL
Intervention: Crocin (30 mg tablets, three consecutive doses, 1 day before to 1 day after CM exposure)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (standard hydration therapy only)
Number of subjects: 110
Study: 32571229

Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills motor scale
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 30s-Chair Stand Test
Number of subjects: 144

Group type: COMPARATOR
Intervention: Other measures
Number of subjects: 144
Study: 36435539

Group type: EXPERIMENTAL
Intervention: Imaginal retraining (IR)
Number of subjects: 384
Study: 34467824

Group type: EXPERIMENTAL
Intervention: Enhanced Care Transitions Intervention (ECTI) with peer support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care Transitions Intervention (CTI)
Number of subjects: 0
Study: 36214036

Group type: EXPERIMENTAL
Intervention: Primary care received during COVID-19 lockdown
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Home delivery of chronic medication
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Referrals to community health workers and telephonic patient follow-up
Number of subjects: 49
Study: 33788457

Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture therapy applied at Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Hegu (LI 4), Sanyinjiao (SP 6), 30 min each treatment, once a day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Opioid painkillers (oxycodone hydrochloride prolonged-release tablet or morphine sulfate sustained-release tablet)
Number of subjects: 60
Study: 35311718

Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) 5 times a week for 30 minutes each time over a period of 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CT) receiving medication and routine rehabilitation training
Number of subjects: 32
Study: 32949864

Group type: EXPERIMENTAL
Intervention: Targeted treatment (TT) with fenbendazole at 22, 27 and 36 weeks post‐placement (WPP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional treatment (CT) at 27 WPP
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untreated (UT) control groups
Number of subjects: 6
Study: 33057739

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) for 30 min once a week for 12 weeks.
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (Kegel exercises and bladder retraining)
Number of subjects: 106
Study: 35476239

Group type: EXPERIMENTAL
Intervention: Dynamic real-time feedback via daily computer-generated email to providers regarding their HCAHPS performance and peer comparison.
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Control group (no dynamic feedback).
Number of subjects: 1110
Study: 34238221

Group type: EXPERIMENTAL
Intervention: RITS toolbox
Number of subjects: 0
Study: 32343631

Group type: EXPERIMENTAL
Intervention: HOPE–Helping Others through Purpose and Engagement (3-month volunteer placement)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 74
Study: 35398397

Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based intervention (IMI) + treatment as usual (TAU)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 210
Study: 34376508

Group type: EXPERIMENTAL
Intervention: Experimental treatment in CombiRx (relapsing-remitting MS)
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Experimental treatment in ASCEND (secondary progressive MS)
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Experimental treatment in PROMISE (primary progressive MS)
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Experimental treatment in INFORMS (primary progressive MS)
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Age (per year increase)
Number of subjects: 3810
Study: 33351814

Group type: EXPERIMENTAL
Intervention: Zung Self‐Assessment Scale for Anxiety (SAS)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Univariate analysis
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1637
Study: 35437129

Group type: EXPERIMENTAL
Intervention: Ceiling nets and bed nets provided to 1,073 houses
Number of subjects: 2235

Group type: COMPARATOR
Intervention: Bed nets only provided to 1,162 houses
Number of subjects: 2235
Study: 33560104

Group type: EXPERIMENTAL
Intervention: Bilateral lower extremity DUS surveillance on days 1, 3, and 7 and weekly during hospitalization (US)
Number of subjects: 1989

Group type: COMPARATOR
Intervention: No surveillance (NoUS)
Number of subjects: 1989
Study: 35450838

Group type: EXPERIMENTAL
Intervention: HBR+ patients
Number of subjects: 787

Group type: COMPARATOR
Intervention: HBR- patients
Number of subjects: 787
Study: 33358159

Group type: COMPARATOR
Intervention: 0% chopped grass hay
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5% chopped grass hay
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10% chopped grass hay
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0% to 5% hay
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5% to 10% hay
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall digestibility
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Digestibility of starch, sugar, and fat
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Digestibility changes with age
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Digestive capacity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5% chopped hay
Number of subjects: 48
Study: 33958679

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on the primary motor cortex (M1) for 20 min at 2 mA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on the left dorsolateral prefrontal cortex (dlPFC) for 20 min at 2 mA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo condition (SHAM) for 20 min at 2 mA
Number of subjects: 18
Study: 33369459

Group type: EXPERIMENTAL
Intervention: Airway Block (AB) - n=30, Superior laryngeal nerve block bilaterally and recurrent laryngeal nerve block transtracheally with Inj 2% Lignocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Airway Nebulization (AN) - n=30, Airway nebulized with 4% Lignocaine with ultrasonic nebulizer
Number of subjects: 60
Study: 35548404

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation surgical nursing combined with PDCA circulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional nursing (Control)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 80
Study: 33217877

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral Jianweixiaoshi tablets
Number of subjects: 60
Study: 34907021

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (25 mg/kg body weight per day) for 12 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 68
Study: 34271401

Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59